Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients (PERICO)
Open, Multicentre,Randomized Phase IV Trial to Evaluate Efficacy/Safety to Extend Treatment Duration With Peginterferon Alfa-2a+High Dose of Ribavirin Supporting Epo β in Treatment of CHC in HIV-HCV Patients Who Not Clear Virus at Week 4
Sponsor: Hospital Carlos III, Madrid
Listed as NCT00526448, this PHASE4 trial focuses on Chronic Hepatitis C and remains ongoing. Sponsored by Hospital Carlos III, Madrid, it has been updated 6 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
First recorded
Jun 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hospital Carlos III, Madrid
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Albacete, Spain , Alcorcón, Spain , Barakaldo, Spain , Barcelona, Spain , Elche, Spain , Ferrol, Spain , Granada, Spain , Huesca, Spain , Jerez de la Frontera, Spain and 22 more locations